Management of engraftment arrhythmias associated with human-induced pluripotent stem cell-derived cardiomyocytes transplantation
Authors' conclusion
The occurrence of EAs was likely driven by an automaticity mechanism, and hiPSC-CM transplantation dose was significantly correlated with EA incidence.
Study context
- Population
- Patients undergoing coronary artery bypass grafting (CABG) combined with hiPSC-CM transplantation or isolated CABG at our hospital between November 2023 and November 2025patients in the experimental group
- Participants
- 24 patients
- Comparison
- EA characteristics were analyzed and compared between the 2 subgroups
- high-dose groupn = 12
- low-dose groupn = 12
Main finding
As reported in the abstract
EAs originating from the cell injection site
Developed engraftment arrhythmias (EAs) (of the 24 patients in the experimental group)
13
54.2%
Further findings
| Outcome | High-dose group | Low-dose group | Control group | P value | |
|---|---|---|---|---|---|
| EA incidence · significantly higher in the high-dose group | 83.3% | 25.0% | Not reported in the abstract | P = 0.012 | control group: not reported in the abstract |
EA heart rate
- Initial paroxysmal EAs, heart rate
- 55-96 bpm, 72.15 ± 9.77 bpm
- Sustained episodes, max heart rate
- max 111-185 bpm, 146.00 ± 21.02 bpm
Hemodynamics during EA episodes
- No hemodynamic abnormalities were detected in any patient during EA episodes
Atrial pacing and electrical cardioversion
- Atrial pacing and electrical cardioversion reduced EA rate but failed to terminate EAs
Association of hiPSC-CM dose with EA occurrence (univariate logistic regression)
- Odds ratio for hiPSC-CM dose
- 15.00; 95% confidence interval, 2.02-111.17; P = .008
- Univariate
Original publication
Management of engraftment arrhythmias associated with human-induced pluripotent stem cell-derived cardiomyocytes transplantation. Heart Rhythm. Published 4 July 2026. doi:10.
Summarised from the published abstract; every number is checked against it